Namba N - Search Results

1

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Namba N, Kubota T, Muroya K, Tanaka H, Kanematsu M, Kojima M, Orihara S, Kanda H, Seino Y, Ozono K. Namba N, et al. J Endocr Soc. 2022 Feb 11;6(5):bvac021. doi: 10.1210/jendso/bvac021. eCollection 2022 May 1. J Endocr Soc. 2022. PMID: 35356008 Free PMC article.

2

The inwardly rectifying potassium channel subunit Kir2.2v (KCNJN1) maps to 17p11.2-->p11.1.

Namba N, Mori R, Tanaka H, Kondo I, Narahara K, Seino Y. Namba N, et al. Cytogenet Cell Genet. 1997;79(1-2):85-7. doi: 10.1159/000134688. Cytogenet Cell Genet. 1997. PMID: 9533018

3

Efficacy of growth hormone therapy for patients with skeletal dysplasia.

Kanazawa H, Tanaka H, Inoue M, Yamanaka Y, Namba N, Seino Y. Kanazawa H, et al. Among authors: namba n. J Bone Miner Metab. 2003;21(5):307-10. doi: 10.1007/s00774-003-0425-7. J Bone Miner Metab. 2003. PMID: 12928832 Clinical Trial.

4

[GH receptor and its downstream signal transduction].

Kawai M, Namba N, Ozono K. Kawai M, et al. Among authors: namba n. Nihon Rinsho. 2005 Oct;63 Suppl 10:561-5. Nihon Rinsho. 2005. PMID: 16279701 Review. Japanese. No abstract available.

5

[Management of hypoparathyroidism].

Namba N, Ozono K. Namba N, et al. Clin Calcium. 2005 Dec;15(12):17-22. Clin Calcium. 2005. PMID: 16322669 Review. Japanese.

6

Lack of puberty despite elevated estradiol in a 46,XY phenotypic female with Frasier syndrome.

Miyoshi Y, Santo Y, Tachikawa K, Namba N, Hirai H, Mushiake S, Nakajima S, Michigami T, Ozono K. Miyoshi Y, et al. Among authors: namba n. Endocr J. 2006 Jun;53(3):371-6. doi: 10.1507/endocrj.k05-180. Epub 2006 May 23. Endocr J. 2006. PMID: 16717397 Free article.

7

Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway.

Kawai M, Namba N, Mushiake S, Etani Y, Nishimura R, Makishima M, Ozono K. Kawai M, et al. Among authors: namba n. J Mol Endocrinol. 2007 Feb;38(1-2):19-34. doi: 10.1677/jme.1.02154. J Mol Endocrinol. 2007. PMID: 17242167

8

Wnt/Lrp/beta-catenin signaling suppresses adipogenesis by inhibiting mutual activation of PPARgamma and C/EBPalpha.

Kawai M, Mushiake S, Bessho K, Murakami M, Namba N, Kokubu C, Michigami T, Ozono K. Kawai M, et al. Among authors: namba n. Biochem Biophys Res Commun. 2007 Nov 16;363(2):276-82. doi: 10.1016/j.bbrc.2007.08.088. Epub 2007 Aug 27. Biochem Biophys Res Commun. 2007. PMID: 17888405

9

Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter.

Namba N, Etani Y, Kitaoka T, Nakamoto Y, Nakacho M, Bessho K, Miyoshi Y, Mushiake S, Mohri I, Arai H, Taniike M, Ozono K. Namba N, et al. Eur J Pediatr. 2008 Jul;167(7):785-91. doi: 10.1007/s00431-007-0589-6. Epub 2007 Sep 25. Eur J Pediatr. 2008. PMID: 17899191

10

Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T. Endo I, et al. Among authors: namba n. Bone. 2008 Jun;42(6):1235-9. doi: 10.1016/j.bone.2008.02.014. Epub 2008 Mar 5. Bone. 2008. PMID: 18396126

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters